PCDHB15 (Protocadherin Beta 15) is a member of the cadherin superfamily involved in cell adhesion and neural development. The PCDHB15 Antibody (13583-1-AP) from Proteintech is a polyclonal antibody validated for immunohistochemistry (IHC) and ELISA applications in mouse models .
The HPA-15 system resides on the CD109 glycoprotein and is associated with immune-mediated thrombocytopenia. Alloantibodies against HPA-15a/HPA-15b are implicated in fetal/neonatal alloimmune thrombocytopenia (FNAIT) and platelet transfusion refractoriness .
Gene Frequencies: HPA-15a (51.2%), HPA-15b (48.8%) in blood donors .
Incidence: HPA-15 alloantibodies account for 6.2% of platelet alloimmunizations, with higher prevalence in polytransfused patients (3.0%) vs. FNAIT cases (0.22%) .
Detection Challenges: Low CD109 expression and instability during storage complicate serological testing .
| Method | Sensitivity | Specificity | Key Advantage |
|---|---|---|---|
| CL-MR-MAIPA Assay | High | High | Detects HPA-15a/HPA-15b via cell lines |
| CL-IC-MPHA Assay | Moderate | High | Rapid (<2 hours), uses MPHA principle |
Synopsis: The CL-IC-MPHA assay simplifies workflow but has 2–8x lower sensitivity than CL-MR-MAIPA .
Therapeutic Potential: No direct therapeutic applications reported, but protocadherins are explored in neurodevelopmental disorders.
Pathology: Anti-HPA-15b antibodies are linked to platelet transfusion refractoriness .
Case Study: Three polytransfused patients developed anti-HPA-15b without other platelet-reactive antibodies, suggesting isoimmunization risk .
| Application | Protocol Highlights |
|---|---|
| IHC | Antigen retrieval with TE buffer (pH 9.0) or citrate buffer (pH 6.0); 1:50–1:500 dilution. |
| ELISA | Titration required for optimal results; no standard protocol provided. |
| Feature | PCDHB15 Antibody | HPA-15 Antibody System |
|---|---|---|
| Primary Use | Neural research | Clinical diagnostics/therapeutics |
| Species Reactivity | Mouse | Human |
| Commercial Availability | Yes (Proteintech 13583-1-AP) | Limited to specialized assays |
| Disease Association | Neurodevelopmental studies | Thrombocytopenia, transfusion refractoriness |
PCDHB15: Functional studies to elucidate its role in neurodevelopmental pathways.
HPA-15: Development of point-of-care assays for rapid detection in transfusion medicine.